About this trial
This trial looks at how well pembrolizumab works for treating high-grade cervical intraepithelial neoplasia (CIN). Pembrolizumab is a type of immunotherapy. It helps the body's immune system fight against cancer and may stop tumor cells from growing.
This is an NCT Phase 2 trial, meaning it is looking at how well pembrolizumab works and its safety. The trial is FDA-regulated and aims to include about 25 participants.
Who can join
Women who are at least 21 years old can join this study. They need to have a confirmed diagnosis of CIN grade 2 or 3. Participants must not be pregnant or breastfeeding. They also need to be able to provide a tissue sample and agree to some follow-up procedures. The trial team will confirm eligibility before participation.
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
All participants will receive pembrolizumab through an IV. This treatment is given once every six weeks for a total of four cycles, which lasts for 24 weeks. There are no separate treatment groups in this study.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
University of California at Los Angeles / Jonsson Comprehensive Cancer Center
Los Angeles, California